Physician profile
Debra Hall
NPI 1700936655
$1,594.60
in general payments reported to CMS, 2019-2025
21 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.25 · 2023: $280 · 2024: $818 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $440.39 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $208.24 | 2024 | |
| Daiichi Sankyo INC. | $153.36 | 2023-2025 | Injectafer |
| Amgen INC. | $137.78 | 2023-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $118.94 | 2024-2025 | Spravato |
| Merck Sharp & Dohme LLC | $74.15 | 2022-2024 | Delstrigo, Pifeltro, Dificid |
| Axsome Therapeutics, INC. | $60.02 | 2025 | Auvelity |
| Exact Sciences Corporation | $56.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Biotech, INC. | $44.88 | 2023-2025 | Tremfya |
| Neurocrine Biosciences, INC. | $41.79 | 2025 | |
| Lilly USA, LLC | $36.34 | 2023-2025 | Jardiance, Emgality, Zepbound |
| Pfizer INC. | $32.03 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.45 | 2022 | |
| Edwards Lifesciences Corporation | $28.03 | 2023 | Sapien 3 Ultra Resilia |
| Indivior INC. | $27.39 | 2024 | Sublocade |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $21.22 | 2024 | |
| Theratechnologies INC. | $19.47 | 2023 | Egrifta, Trogarzo |
| Sanofi Pasteur INC. | $17.00 | 2025 | |
| Alk-Abello, INC | $16.51 | 2023 | Odactra, Grastek |
| Vanda Pharmaceuticals INC. | $15.97 | 2025 | Fanapt |
| Astrazeneca Pharmaceuticals Lp | $13.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.